Drug Profile
AVX 701
Alternative Names: AVX701; Cancer vaccine VRP-CEA - AlphaVax; Carcinoembryonic antigen [CEA(6D)]-expressing virus-like replicon particle (VRP) immunotherapy - AlphaVax; CEA(6D) VRP vaccine - AlphaVax; VRP-CEA vaccine - AlphaVaxLatest Information Update: 22 Jul 2019
Price :
$50
*
At a glance
- Originator AlphaVax
- Developer AlphaVax; Duke University Medical Center
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Colorectal cancer
Most Recent Events
- 01 Jul 2019 Duke University completes a phase I trial in Colorectal cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT01890213)
- 22 Sep 2015 Phase-I development for Colorectal cancer (Late-stage disease, Second-line therapy or greater) is ongoing in USA (NCT01890213)
- 30 Nov 2013 Duke University initiates enrolment in a phase I trial for Colorectal cancer (late-stage disease) in the USA (NCT01890213)